Skip to content

Advertisement

  • Research
  • Open Access

rs4889 polymorphism in KISS1 gene, its effect on polycystic ovary syndrome development and anthropometric and hormonal parameters in Saudi women

  • 1,
  • 1Email author,
  • 2,
  • 3 and
  • 4
Journal of Biomedical Science201825:50

https://doi.org/10.1186/s12929-018-0452-2

  • Received: 8 January 2018
  • Accepted: 22 May 2018
  • Published:

Abstract

Background

Kisspeptin is involved in female reproduction. This study was designed to i- estimate kisspeptin levels in women with polycystic ovary syndrome (PCOS), in comparison with controls, ii- study the correlations between kisspeptin and PCOS-related reproductive hormones, and iii- investigate the relation between KISS1 gene polymorphisms and hormone levels in women suffering from PCOS.

Methods

The investigation was a clinically designed study on 28 women with PCOS, and 30 normal, healthy women with no signs of PCOS as controls. Blood samples were collected between day 3 and day 6 of the menstrual cycle in both groups at 8:00 a.m., and circulating levels of LH, FSH and kisspeptin were estimated. DNA was extracted from whole blood and all coding exons of KISS1 gene were sequenced.

Results

Women with PCOS had higher LH levels and BMI compared to controls. Plasma kisspeptin levels were positively correlated with LH levels. There was no statistically significant difference between the groups in terms of kisspeptin and FSH levels. The SNP rs4889 C/G, a non-synonymous SNP, was investigated in the PCOS group. The frequency of GG genotype was significantly higher in the PCOS compared to the controls. These patients were more obese, had higher kisspeptin and FSH levels.

Conclusion

The results of the study show that the genetic variation of KISS1 gene may be a factor contributing to PCOS development. The association between the gene and the gene variation and PCOS need further validation in large-scaled and functional studies.

Keywords

  • KISS1 gene
  • Kisspeptin
  • LH
  • FSH
  • GPR54
  • PCOS

Background

Kisspeptin is a 54-amino-acid peptide encoded by the KISS1 gene, and is also known as metastin [1, 2], which was first isolated from the human placenta in 2001 [3]. Kisspeptin action is exerted by a trans-membrane G-protein coupled receptor, named GPR54, AXOR12, or HoT7T175 [4]. Loss of KISS1 gene function is reported to be associated with hypogonadotropic hypogonadism in humans and animal models [5, 6]. Binding of kisspeptin to its receptor (GPR54) in the GnRH neurons in the hypothalamus, results in the stimulation of gonadotropin release, which in turn binds to the GnRH receptors in the pituitary and influences the release of LH and FHS [7]. These hormones act on the gonads and influence estrogen, testosterone and progesterone release. Hence, kisspeptin has been shown to regulate the secretion of luteinizing hormone (LH) during the promotion of ovulation [8] by stimulating gonadotropin releasing hormone (GnRH) from the hypothalamus [9, 10].

The polycystic ovary syndrome (PCOS) is a common heterogeneous disorder affecting women, with a prevalence of 6–12% in women of reproductive age [11]. It is of complex pathogenesis, characterized by hypothalamic-pituitary disturbances in gonadotropin secretion, specifically increased LH levels [12, 13], chronic anovulation, and polycystic ovaries (PCO) on ultrasound. In addition, patients frequently suffer from hyperinsulinemia, insulin resistance [14], type 2 diabetes mellitus (DM), cardio-vascular disease and infertility [15, 16]. Given the complex relationship between kisspeptin and hypothalamic-pituitary gonadal axis, the present study aimed to investigate the relation between KISS1, BMI, FSH and LH and the influence of KISS1 gene polymorphisms on these parameters in normal women and those suffering from PCOS.

Methods

Subjects

The samples were collected from Al-Hira Hospital in Makkah Al Mukarama, from 58 Saudi women volunteers aged 19–36 after obtaining Ethical Committee approval, from the Institutional Review Board. Each participant gave a written informed consent prior to enrolment in the study. A total of 58 Saudi women volunteers aged 19–36 years were recruited. Cases were 28 Saudi women attending the outpatient clinics and fulfilling the following criteria:
  • Oligomenorrhoea (cycle duration between 35 days to 3 months).

  • Transvaginal ultrasound image of enlarged ovaries with > 10 cysts in the largest plane; each measuring <I0mm in diameter scattered around an echodense thickened stroma [17]

  • None had received any drugs known to interfere with hormonal concentrations for at least 3 months before the study.

Controls were 30 Saudi women volunteers representing cross section of Saudi society. All subjects were healthy, had spontaneous onset of puberty and sexual development, with regular menstrual cycle, and no history of gastrointestinal or endocrine disorders.

Anthropometric measurements

Anthropometric measurements included body weight, height and body mass index (BMI), (weight in Kg divided by height in m2).

Laboratory methods

Blood samples were collected between day 3 and day 6 of a menstrual cycle in the PCOS and control groups, all blood samples were obtained at 8:00 a.m. (This ensured obtaining the true level of the reproductive hormones, as these hormones show variations with the days of the menstrual cycle). Five milliliter of blood was drawn by venipuncture in red top tube for kisspeptin, FSH and LH estimations.

In addition, 5 mL of blood was collected in EDTA-coated tubes for DNA extraction. All blood samples for each subject were immediately centrifuged, and plasma, serum and buffy coat were stored at − 80 °C until analysis. Kisspeptin levels were measured with an enzyme-linked immunoassay kit (ELISA kit, Phoenix Pharmaceuticals Inc., Belmond, CA), after extraction with Phoenix Peptide sep-columns (RK-Sepcol-2). FSH and LH levels were measured with an enzyme-linked immunoassay kit (ELISA kit, Human, cat.No.65205.GER).

Genotyping of KISS1 gene polymorphism

Genomic DNA was extracted from peripheral blood leucocytes using commercially available Puregene Blood Kit (QIAGEN, cat. No. 158389, USA). Polymorphism was determined by sequencing following polymerase chain reaction (PCR), using forward and reverse primers. The primers were designed using PRIMER 3 program and the sequence of each primer was as follows:

F: 5′- ACCTGCCGAACTACAACTGG-3′; R: 5’-TGAAGGAACAGGCGGTTAGT -3’.

The PCR conditions consisted of initial denaturation step at 95 °C for 15 min, followed by 34 cycles of denaturation at 95 °C for 1 min, annealing at 60 °C for 1 min, and extension at 72 °C for 1 min, with final extension of 10 min at 72 °C. A PCR product of 353 bp was obtained. Nucleotide sequencing was carried out using the ABI Big Dye Terminator protocol on ABI 3100 Avant Genetic Analyzer.

Statistical analyses

The descriptive characteristics of the group variables were expressed as mean ± SEM. The comparisons between PCOS patients and their matched controls were carried out using the independent t-test and ANOVA test with respect to all variables. Pearson Correlation Coefficients was used to study the correlation between Kisspeptin, BMI and other studied variables. Genotype and allele frequencies were calculated manually https://ihg.gnf.de/cgi-bin/hw/hwa1.pl. Significance of the difference in the result of POCS cases and controls was obtained using Fisher’s Exact test (two-tailed) and odds ratios, 95% confidence intervals, χ2 and p value were obtained. All statistical analyses were performed by using SPSS for Windows (version 9.3).

Results

Basic anthropometrics and hormonal features of the study group are summarized in Table 1. Women with PCOS had significantly higher weight, BMI and LH level compared to the control group (p < .0001). No significant differences in FSH and kisspeptin level between groups were observed. Kisspeptin level were higher in PCOS women compared to control group, but not significantly. Kisspeptin level were found to be positively correlated with LH level in the PCOS patients (r = 0.604; p = 0,005, control: r = 0.409; p = 0.007). Correlations between kisspeptin level, hormonal and anthropometric measurement of women studied are summarized in Table 2. Direct sequencing of KISS1 gene revealed several SNPs. The SNP rs4889 (C/G) was detected more frequently in PCOS group than in control, and this nonsynonymous SNP results in the substitution of P81R. Distribution of rs4889 C/G in KISS1 gene and the allele and genotype frequencies in PCOS and control groups are summarized in Table 3. Statistically significant differences were observed for the alleles (p = 0.0057), and genotype frequency between PCOS and controls. Allele C showed higher frequency in PCOS group (37.5%) than control group (15%). The individuals with the different genotypes were separated and the levels of the anthropometric and hormonal parameters and kisspeptin were separately analyzed for each genotype. Table 4 presents the results of the study variables in the different rs4889 genotypes (CC, CG and GG) in Saudi women with PCOS and Control groups. Statistically significant difference were observed in the wild type GG in women with PCOS in weight (Kg) (75.83 ± 11.42vs. 57.59 ± 10.07, p < .0001), and in BMI (wt/ht2) (48.32 ± 6.73 vs 35.01 ± 8.04, p < .0001). Statistically significant difference were observed in the heterozygous CG in LH level (13.73 ± 3.35 vs. 8.741 ± 1.28, P < .0001). The effect of the different genotypes of rs4889 on the level of of kisspeptin was studied and as shown in the Table 4. The kisspeptin level did not differ significantly in individuals with the CC, CG and GG genotypes in PCOS group and GG and CG in control group. Only one control had CC genotype and was not included in the calculations.
Table 1

Comparisons of clinical parameters amongst PCOS and control group

Variable

PCOS Group

(n = 28)

Mean ± SD))

Control Group

(n = 30)

Mean ± SD))

P-value

Age (years)

29.4 ± 3.93

26.7 ± 3.6

0.008

Weight (Kg)

72.63 ± 12.8

59.87 ± 10.8

0.0001

Height (cm)

155.9 ± 6.9

161.5 ± 4.1

0.001

BMI (Kg\m2)

46.04 ± 7.3

36.6 ± 8.17

0.0001

FSH (IU\I)

6.81 ± 5.4

5.7 ± 1.95

0.325

LH (IU\I)

15.12 ± 3.7

8.73 ± 1.16

0.0001

Kisspeptin (pg\mL)

0.43 ± .15

0.39 ± .07

0.178

Table 2

Correlations between kisspeptin level, hormonal and anthropometric measurement of PCOS patients and control group

Correlation between kisspeptin and

PCOS Group

(n = 28)

Controls Group

(n = 30)

r

p

Sig

r

P

Sig

Age (years)

0.182

0.355

NS

0.083

0.663

NS

Weight (Kg)

0.111

0.575

NS

0.152

0.422

NS

Height (cm)

−0.118

0.549

NS

−0.177

0.351

NS

BMI (Kg/m2)

0.165

0.401

NS

0.109

0.567

NS

FSH (IU/I)

0.049

0.804

NS

0.225

0.231

NS

LH (IU/I)

0.604

0.005

S

0.409

0.007

S

NS non-significant = p > 0.05, S significant = p ≤ 0.05, r correlation coefficient

Table 3

Frequencies of allele and genotypes of rs4889 C/G in KISS1 gene in PCOS and control groups

Variation

Control

(N = 30)

Case

(28)

OR

CI

χ 2

P-value

CC

1 (3.3)

4 (14.3)

8.0

0.79–80.4

3.96

0.046

CG

7 (23.3)

13 (46.4)

3.714

1.15–11.96

5.04

0.024

GG

22 (73.3)

11 (39.4)

0.125

0.012–1.26

3.96

046

CG + GG

29 (0.48)

24 (0.43)

0.207

0.02–1.98

2.21

0.137

C

9 (0.15)

21 (0.375)

3.4

1.4–8.3

7.65

0.006

G

51 (0.85)

35 (0.625)

0.294

0.12–0.72

7.65

0.006

OR odds ratio, CI confidence intervals, χ 2 chi square, P significance

Table 4

Level of anthropometric parameters and hormones in different genotypes of rs4889 C/G in KISS1 gene in Saudi women with PCOS and Control groups

Variable

PCOS Group

(n = 28)

(Mean ± SD)

Control Group

(n = 30)

(Mean ± SD)

P-value

GG

n = 11

CG

n = 13

CC

n = 4

GG

n = 22

CG

n = 7

GG

CG

CC

Weight (Kg)

75.8 ± 11

74.1 ± 13

58.8 ± 4.1

57.5 ± 10

68.4 ± 9.6

0.0001**

0.362

0.157

Height (cm)

156. ± 6.8

156 ± 7.5

152 ± 5.91

162 ± 3.9

158.8 ± 3.5

0.007*

0.660

0.468

BMI (Kg/m2)

48.3 ± 6.7

47.2 ± 7.5

38 ± 1.76

35 ± 8

42.6 ± 6.43

0.0001**

0.219

0.157

FSH (IU/I)

6.52 ± 5.6

7.64 ± 5.8

4.9 ± 4.02

5.8 ± 2

5.5 ± 1.4

0.879

0.475

1.00

LH (IU/I)

13.7 ± 3.3

16.2 ± 3.8

15.3 ± 3.7

8.7 ± 1.2

8.6 ± 0.89

0.0001**

0.0001**

0.147

kisspeptin (pg\mL)

0.38 ± 0.2

0.43 ± 0.1

0.35 ± 0.18

0.37 ± .06

0.45 ± 0.06

0.349

0.968

1.00

There was only 1 sample with a CC genotype in the control group, and was not used in the comparison

*p-value< 0.05; **p-value< 0.001

Discussion

The present study investigated plasma kisspeptin levels in Saudi women with and without PCOS and studied the nature of correlation between kisspeptin, anthropometric parameters and PCOS-related reproductive hormones. It also evaluated the sequence of exons in the KISS-1 gene and compared the frequency of rs4889 C/G, a non-synonymous SNP, in PCOS and controls. Our investigation showed that the level of kisspentin was slightly higher in females with PCOS, though the results compared to the control group were not significantly different. Three previous studies [1820] reported higher kisspeptin levels in women with PCOS. Another study [21] reported lower levels in women with PCOS as compared to controls. Yerlikaya et al., [22] study and our study did not support these findings. This may be the result of the obesity and insulin resistance that may have negative impact on kisspeptin levels.

The Kiss-1 system has emerged in the recent years as a fundamental player in the control of the reproductive axis, with essential roles in differentiation and pubertal activation of the reproductive system as well as key functions in the regulation of ovulation and fertility [18]. Kisspeptin has been recently associated with increased GnRH and regulates the secretion of LH during the promotion of ovulation [23, 24]. PCOS is a condition associated with disordered hypothalamic-pituitary-gonadal axis, higher LH levels, compared to ovulatory women without the syndrome [25, 26]. The present study evaluated the possible role of kisspeptin in the pathophysiology of PCOS and showed the correlation between levels of kisspeptin and LH. Several groups have now reported that kisspeptin administered either centrally or peripherally, stimulate gonadotropin secretion. Similar observations were reported in the rat [27, 28], sheep [29], monkey [30, 31] and more recently, the human male [32]. Our study showed that LH levels were higher in PCOS women compared to controls, and plasma kisspeptin levels were positively correlated with LH levels. It was consistent with the idea that kisspeptin may stimulate LH secretion, although the way of direct pituitary effects of kisspeptin in the control of gonadotropin secretion remains controversial [33, 34]. In another study conducted by Panidis et al., [21], it was found that LH levels were significantly higher in PCOS groups compared to controls. This finding was in line with the results of the present study. However, no significant correlation between plasma kisspeptin and LH levels was observed in their study, and they also found that obese and overweight women with PCOS had significantly lower kisspeptin levels compared to normal weight women with the syndrome. These conclusions are contradictory to our study, possibly due to differences in the BMI in these studies as well as methodological differences. Additionally, small sample size and the heterogeneity of the study groups are the limitations of these previous studies. Plasma kisspeptin levels were measured by Chen et al. [19] in 42 women with PCOS (23 adult, 19 adolescents) and 20 adolescent controls to investigate the possible correlations between kisspeptin and PCOS related reproductive and metabolic disturbances. Their results suggested that plasma kisspeptin levels were increased in lean adolescent and adult women with PCOS compared with lean adolescent control group. Our study did not support these findings. Moreover, LH levels of both adult and adolescent PCOS women were higher than that of adolescent controls and kisspeptin showed a positive correlation with LH similar to the findings of our study. Some researchers have demonstrated that kisspeptin may play a key role in the activation of the gonadotropic axis at puberty [35, 36]. So elevated kisspeptin levels of adolescent PCOS may play a role as a marker to recognize PCOS in adolescents more clearly and sometimes at an earlier stage. In the study of Chen and coworkers [19], the number of the controls was relatively small and no adult controls were involved. Therefore, it needs further research to draw any conclusions. Plasma kisspeptin levels were measured by Jeon et al. [20] in 54 women with PCOS and 36 controls. Their results suggested that plasma kisspeptin levels were significantly higher in the PCOS group than in controls; however, they did not find correlations between kisspeptin and any of the hormones. The data of Yilmaz et al., [18] claimed that women with PCOS exhibited higher kisspeptin levels than controls. Furthermore, kisspeptin concentrations were found to be in a positive correlation with LH levels.

In this study, polymorphism in SNP rs4889 C/G was detected more frequently in PCOS group than in control (p-value = 0.0057). Allele C showed higher frequeny in PCOS group (37.5%) than control group (15%). When the results in different genotypes were compared, the weight and BMI were higher, while the LH level was lower in the GG genotype, in the PCOS patients and the results were significantly different. Kisspeptin was higher in the GG genotype but the results were not significantly different. When compared with the control group, the weight, height and BMI were significantly higher in PCOS carrying GG genotype, compared to the controls with the same genotype. LH was higher in all genotypes in the PCOS, compared to the results in the control group.

rs4889 polymorphism introduced a substitution of proline for arginine at the 81 position. This is a substitution that was observed in kisspeptin-54, but not in the other three forms of kisspeptin (kisspeptin-14, − 13, and − 10). This SNP is found in the coding region and results in the substitution of an imino acid Pro by a basic amino acid Arg. Change in the DNA sequence as a result of this polymorphisms could alter the structure, function and binding capacity of kisspeptin to its receptor GPR54.. Previous studies in Korean and Chinese populations found no relationship between this SNP and CPP [37, 38]. From the results of this study, it appears that rs4889 influences the mechanism by which kisspeptin activates secretion of LH but not FSH. Further studies are necessary to investigate the possible mechanisms involved in kisspeptin function and mode of action.

Conclusion

In conclusion, this study has shown significant relationship between the rs4889 C/G polymorphisms in KISS1 gene and PCOS in Saudi females, where the mutant G allele is highly protective (OR = 0.294; 95% CI = 0.12–0.72, χ2 = 7.65; p = 0.006). The LH levels were higher in the women with PCOS, compared to the controls, and plasma kisspeptin levels positively correlated with LH levels. Within the genotypes of rs4889 the LH levels were significantly lower in the GG compared to the CG and CC genotypes in the PCOS females. The mechanism of kisspeptin for regulating gonadotropin secretion remains unknown. Discrepant findings among the results of the published studies may be attributed to the design and sample size and the demographic and genetic characteristics of the different populations.

The major limitation of our study was the small number of the studied sample. Further studies are warranted, to get a clearer picture of the mechanisms that bring about the interaction between kiss-1 gene and different hormonal parameters.

Declarations

Acknowledgements

The authors extend their appreciation to the National Plan for Science, Technology and Innovation (MAARIFAH), King Abdul-Aziz City for Science and Technology, Kingdom of Saudi Arabia, grant Number No 08-MED 604-2. We thank all the subjects for their cooperation and participation in the study. We would also like to thank all the participants (researchers, technicians and nurses) for their notable contribution.

Funding

This Work was funded by the National Plan for Science, Technology and Innovation (MAARIFAH), King Abdul-Aziz City for Science and Technology, Kingdom of Saudi Arabia, grant Number No 08-MED 604-2.

Availability of data and materials

Due to ethical concerns, the data of the present study cannot be openly available.

Declarations

The study protocol was approved by the local ethical committee Makkah, Kingdom of Saudi Arabia. All participants attending the out-patient Gynecology Clinic were enrolled in the study, after taking their informed consent.

Authors’ contributions

FSA and MHD designed the study, obtained all the needed chemicals, kits and other requirements, conducted all analysis and contributed to the writing of the manuscript. MHD2 enrolled the patients, obtained informed consent, and collected all the clinical data. AME conducted statistical analysis and contributed to the writing of the paper. ASW performed the genetics data analysis and contributed to the writing of the paper. All authors read and approved the final manuscript.

Ethics approval and consent to participate

Ethical approval was obtained from the Institutional Review Board (IRB), Umm Al-Qura University, Makkah, Kingdom of Saudi Arabia (IRB No. 235) and each female was required to sign an informed consent form. All participants gave a written informed consent prior to inclusion in the study.

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
Department of Zoology, Center for Scientific and Medical Female Colleges, King Saud University, P.O. Box 22455, Riyadh, 11495, Saudi Arabia
(2)
Department of Obstetrics & Gynecology, Umm-Al-Qura University, P.O. Box 424, Makkah, 21955, Saudi Arabia
(3)
Department of Biostatistics, Epidemiology &Scientific Computing, King Faisal Specialist Hospital and Research Center, P.O. Box 3354, Riyadh, 11211, Saudi Arabia
(4)
Central Laboratory, Center for Scientific and Medical Female Colleges, King Saud University, P.O. Box 22455, Riyadh, 11495, Saudi Arabia

References

  1. Hori A, Honda S, Asada M, Ohtaki T, Oda K, Watanabe T, et al. Metastin suppresses the motility and growth of CHO cells transfected with its receptor. Biochem Biophys Res Commun. 2001;286:958–63.View ArticlePubMedGoogle Scholar
  2. Lee JH, Miele ME, Hicks DJ, Phillips KK, Trent JM, Weissman BE, et al. KiSS-1, a novel human malignant melanoma metastasis-suppressor gene. J Natl Cancer Inst. 1996;88:1731–7.View ArticlePubMedGoogle Scholar
  3. Ohtaki T, Shintani Y, Honda S, Matsumoto H, Hori A, Kanehashi K, et al. Metastasis suppressor gene KiSS-1 encodes peptide ligand of a G-protein-coupled receptor. Nature. 2001;411:613–7.View ArticlePubMedGoogle Scholar
  4. Muir AI, Chamberlain L, Elshourbagy NA, et al. AXOR12, a novel human G protein-coupled receptor, activated by the peptide KiSS-1. J Biol Chem. 2013;276:28969–75.View ArticleGoogle Scholar
  5. deRoux N, Genin E, Carel JC, Matsuda F, Chaussain JL, Milgrom E. Hypogonadotropic hypogonadism due to loss of function of the KiSS1-derived peptide receptor GPR54. Proc Natl Acad Sci U S A. 2003;100:10972–6.View ArticleGoogle Scholar
  6. Funes S, Hedrick JA, Vassileva G, et al. The KiSS-1 receptor GPR54 is essential for the development of the murine reproductive system. Biochem Biophys Res Commun. 2003;312:1357–63.View ArticlePubMedGoogle Scholar
  7. Babiker A, Al Shaikh A. The role of kisspeptin signalling in control of reproduction in genetically similar species. Sudan J Paediatr. 2016;16(1):9–16.PubMedPubMed CentralGoogle Scholar
  8. Castellano JM, Gaytan M, Roa J, et al. Expression of KiSS-1 in ratovary: putativelocal regulator of ovulation? Endocrinology. 2006;147:4852–62.View ArticlePubMedGoogle Scholar
  9. Matsui H, Takatsu Y, Kumano S, Matsumoto H, Ohtaki T. Peripheral administration of metastin induces marked gonadotropin release and ovulation in the rat. Biochem Biophys Res Commun. 2004;320:383–8.View ArticlePubMedGoogle Scholar
  10. Navarro VM, Castellano JM, Fernández-Fernández R, et al. Characterization of the potent luteinizing hormone-releasing activity of KiSS-1 peptide, the natural ligand of GPR54. Endocrinology. 2005;146:156–63.View ArticlePubMedGoogle Scholar
  11. Wojciechowski P, Lipowska A, Rys P, et al. Impact of FTO genotypes on BMI and weight in polycystic ovary syndrome: a systematic review and meta-analysis. Diabetologia. 2012;55:2636–45.View ArticlePubMedPubMed CentralGoogle Scholar
  12. Panidis D, Koliakos G, Kourtis A, Farmakiotis D, Mouslech T, Rousso D. Serum resistin levels in women with polycystic ovary syndrome. Fertil Steril. 2004;81:361–6.View ArticlePubMedGoogle Scholar
  13. Panidis D, Farmakiotis D, Rousso D, Katsikis I, Kourtis A, Diamanti-Kandarakis E. Serum luteinizing hormone levels are markedly increased and significantly correlated with _4-androstenedione levels in lean women with polycystic ovary syndrome. Fertil Steril. 2005;84:538–40.View ArticlePubMedGoogle Scholar
  14. Goodarzi MO, Korenman SG. The importance of insulin resistance in polycystic ovary syndrome. Fertil Steril. 2003;80:255–8.View ArticlePubMedGoogle Scholar
  15. Franks S. Polycystic ovary syndrome. N Engl J Med. 1995;333:853–61.View ArticlePubMedGoogle Scholar
  16. Ehrmann DA, Barnes RB, Rosenfield RL, Cavaghan MK, Imperial J. Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome. Diabetes Care. 1999;22:141–6.View ArticlePubMedGoogle Scholar
  17. Adam J, Franks S, Polson DW, Mason HD, Abdulwahid N, Tucker M. Multifollicular ovaries: clinical and endocrine features and response to pulstile gonadotrophin·releasing hormone. Lancet. 1985;2:1375–8.View ArticleGoogle Scholar
  18. Yilmaz SA, Se cilmis Kerimoglu O, Pekin A, Incesu F, Dogan NU, Celik C, Unlu A. Metastin levels in relation with hormonal and metabolic profile in patients with polycystic ovary syndrome. Eur J Obstet Gynecol Reprod Biol. 2014;180:56–60.View ArticlePubMedGoogle Scholar
  19. Chen X, Mo Y, Li L, Chen Y, Li Y, Yang D. Increased plasma metastin levels in adolescent women with polycystic ovary syndrome. Eur J Obstet Gynecol Reprod Biol. 2010;149(1):72–6.View ArticlePubMedGoogle Scholar
  20. Jeon YE, Lee KE, Jung JA, et al. Kisspeptin, leptin, and retinol-binding protein 4 in women with polycystic ovary syndrome. Gynecol Obstet Investig. 2013;75:268–74.View ArticleGoogle Scholar
  21. Panidis D, Rousso D, Koliakos G, et al. Plasma metastin levels are negatively correlated with insulin resistance and free androgens in women with polycystic ovary syndrome. Fertil Steril. 2006;85:1778–83.View ArticlePubMedGoogle Scholar
  22. Yerlikaya E, Akin F, Turgut S, Yaylali G, Topsakal S, Ayada C, Hatipoglu C. Plasma kisspeptin levels in polycystic ovary syndrome. Endocr Abstr. 2013;32:618.Google Scholar
  23. Gottsch ML, Cunningham MJ, Smith JT, Popa SM, Acohido BV, Crowley WF, et al. A role for kisspeptins in the regulation of gonadotropin secretion in the mouse. Endocrinology. 2004;145:4073–7.View ArticlePubMedGoogle Scholar
  24. Navarro VM, Castellano JM, Fernandez-Fernandez R, Tovar S, Roa J, Mayen A, et al. Characterization of the potent LH releasing activity of KiSS-1 peptide, the natural ligand of GPR54. Endocrinology. 2005;146:156–63.View ArticlePubMedGoogle Scholar
  25. Diamanti-Kandarakis E, Dunaif A. New perspectives in polycystic ovary syndrome. Trends Endocrinol Metab. 1996;7:267–71.View ArticlePubMedGoogle Scholar
  26. Allahbadia GN, Merchant R. Polycystic ovarian syndrome and impact on health. Mid East Fert Soc J. 2011;16:19–37.Google Scholar
  27. Matsui T, Doi R, Mori T, et al. Metastin and its variant forms suppress migration of pancreatic cancer cells. Biochem Biophys Res Commun. 2004;315:85–92.View ArticleGoogle Scholar
  28. Navarro VM, Castellano JM, Fernandez-Fernandez R, et al. Effects of KiSS-1 peptide, the natural ligand of GPR54, on follicle-stimulating hormone secretion in the rat. Endocrinology. 2005;146:1689–97.View ArticlePubMedGoogle Scholar
  29. Messager S, Chatzidaki EE, Ma D, et al. Metastin directly stimulates gonadotropin- releasing hormone secretion via G proteincoupled receptor 54. Proc Natl Acad Sci U S A. 2005;102:1761–6.View ArticlePubMedPubMed CentralGoogle Scholar
  30. Shahab M, Mastronardi C, Seminara SB, Crowley WF, Ojeda SR, Plant TM. Increased hypothalamic GPR54 signaling: a potential mechanism for initiation of puberty in primates. Proc Natl Acad Sci U S A. 2005;102:2129–34.View ArticlePubMedPubMed CentralGoogle Scholar
  31. Plant TM, Ramaswamy S, DiPietro MJ. Repetitive administration of hypothalamic G protein-coupled receptor 54 with intravenous pulses of metastin in the juvenile monkey (Macaca mulatta) elicits a sustained train of gonadotropin-releasing hormone discharges. Endocrinology. 2006;147:1007–13.View ArticlePubMedGoogle Scholar
  32. Dhillo WS, Chaudhri OB, Patterson M, et al. Metastin-54 stimulates the hypothalamic–pituitary gonadal axis in humanmales. J Clin Endocrinol Metab. 2005;90:6609–15.View ArticlePubMedGoogle Scholar
  33. Irwig MS, Fraley GS, Smith JT, et al. Metastin activation of gonadotropin releasing hormone neurons and regulation of KiSS-1mRNA in the male rat. Neuroendocrinology. 2004;80:264–72.View ArticlePubMedGoogle Scholar
  34. Castellano JM, Navarro VM, Fernandez-Fernandez R, et al. Changes in hypothalamic KiSS-1 system and restoration of pubertal activation of the reproductive axis by metastin in undernutrition. Endocrinology. 2005;146:3917–25.View ArticlePubMedGoogle Scholar
  35. Castellano JM, Navorro VM, Fernandez-Fernandez R, Roa J, Vigo E, Pinedo R, et al. Expression ofhypothalamic Kiss-1 system and rescue of defective gonadotropic responses by Kisspeptin in Streptozotocin-induced diabetic male rats. Diabetes. 2006;55:2602–10.Google Scholar
  36. Balen AH, Dunger D. Pubertal maturation of the internal genitalia. Ultrasound Obstet Gynaecol. 1995;6:164–5. [Commentary]View ArticleGoogle Scholar
  37. Ko JM, Lee HS, Hwang JS. KISS1 gene analysis in Korean girls with central precocious puberty: a polymorphism, p.P110T, suggested to exert a protective effect. Endocr J. 2010;57:701–9.View ArticlePubMedGoogle Scholar
  38. Luan X, Zhou Y, Wang W, Yu H, Li P, Gan X, Wei D, Xiao J. Association study of the polymorphisms in the KISS1 gene with central precocious puberty in Chinese girls. Eur J Endocrinol. 2007;157:113–8.View ArticlePubMedGoogle Scholar

Copyright

© The Author(s). 2018

Advertisement